Orogen Royalties Inc

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2020-01-01

Employees: 10K

Market Cap: -

Website: http://www.organon.com

Introduction: Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Clinical Trials

Dose-Ranging Study of Mometasone Furoate (MK-0887/SCH 032088) Nasal Spray in the Treatment of Children (Ages 6-11) With Seasonal Allergic Rhinitis (C95-161)

Phase 3

Completed

Conditions: Rhinitis, Allergic, Seasonal

Interventions: Drug: Mometasone furoate nasal spray
Drug: Beclomethasone dipropionate nasal spray
Drug: Placebo nasal spray
Drug: Chlorpheniramine maleate syrup

First Posted Date: 2019-03-19

Last Posted Date: 2022-02-09

Lead Sponsor: Organon and Co

Target Recruit Count: 679

Registration Number: NCT03879772

Efficacy and Safety Study of Ezetimibe (SCH 58235, MK-0653) in Addition to Atorvastatin in Participants With Coronary Heart Disease or Multiple Cardiovascular Risk Factors (P00693/MK-0653-030)

Phase 3

Completed

Conditions: Hypercholesterolemia

Interventions: Drug: Atorvastatin
Drug: Ezetimibe
Drug: Placebo for Ezetimibe
Drug: Placebo for Atorvastatin

First Posted Date: 2019-03-07

Last Posted Date: 2024-05-10

Lead Sponsor: Organon and Co

Target Recruit Count: 621

Registration Number: NCT03867318

An Efficacy and Safety Study of Ezetimibe (MK-0653, SCH 58235) in Addition to Atorvastatin Compared to Placebo in Participants With Primary Hypercholesterolemia (MK-0653-013)

Phase 3

Completed

Conditions: Hypercholesterolemia

Interventions: Drug: Atorvastatin 10 mg
Drug: Ezetimibe 10 mg
Drug: Atorvastatin 80 mg
Drug: Placebo
Drug: Atorvastatin 40 mg
Drug: Atorvastatin 20 mg

First Posted Date: 2019-03-07

Last Posted Date: 2024-05-10

Lead Sponsor: Organon and Co

Target Recruit Count: 628

Registration Number: NCT03867110

Onset of Action of Mometasone Furoate (MK-0887/SCH 032088) Nasal Spray Compared With Placebo in Seasonal Allergic Rhinitis (C93-184)

Phase 3

Completed

Conditions: Rhinitis, Allergic, Seasonal

Interventions: Drug: placebo nasal spray
Drug: mometasone furoate nasal spray

First Posted Date: 2019-03-04

Last Posted Date: 2022-02-09

Lead Sponsor: Organon and Co

Target Recruit Count: 201

Registration Number: NCT03861559

Safety and Efficacy of Mometasone Furoate Nasal Spray With the Addition of Loratadine Versus Placebo in Participants With Seasonal Allergic Rhinitis (C94-145)

Phase 3

Completed

Conditions: Rhinitis, Allergic

Interventions: Drug: Mometasone furoate nasal spray (MFNS)
Drug: Placebo tablet
Drug: Placebo nasal spray
Drug: Loratadine

First Posted Date: 2019-02-26

Last Posted Date: 2022-02-09

Lead Sponsor: Organon and Co

Target Recruit Count: 704

Registration Number: NCT03855228

Safety and Efficacy of Mometasone Furoate (SCH 032088) vs Beclomethasone Dipropionate or Placebo in Seasonal Allergic Rhinitis (C93-013)

Phase 3

Completed

Conditions: Seasonal Allergic Rhinitis

Interventions: Drug: Mometasone Furoate (MF)
Drug: Beclomethasone Dipropionate (BDP)
Drug: Placebo

First Posted Date: 2019-02-26

Last Posted Date: 2022-02-09

Lead Sponsor: Organon and Co

Target Recruit Count: 345

Registration Number: NCT03855189

Ezetimibe (EZ)/Atorvastatin (Ator) (MK-0653C) vs. Ator in Chinese Hypercholesterolemic Participants (MK-0653C-439)

Phase 3

Completed

Conditions: Hypercholesterolemia

Interventions: Combination Product: EZ 10 mg/Ator 10 mg
Drug: Atorvastatin
Combination Product: EZ 10 mg/Ator 20 mg
Drug: Placebo for FDC EZ/Ator
Drug: Placebo for atorvastatin

First Posted Date: 2018-12-07

Last Posted Date: 2024-05-16

Lead Sponsor: Organon and Co

Target Recruit Count: 454

Registration Number: NCT03768427

Locations: 🇨🇳
Central People s Hospital of Siping ( Site 0046), Siping, Jilin, China
🇨🇳
The First Affiliated Hospital of Baotou Medical College ( Site 0025), Baotou, Anhui, China
🇨🇳
Chongqing General Hospital ( Site 0037), Chongqing, Chongqing, China

and more 27 locations

Efficacy and Safety of Corifollitropin Alfa (MK-8962) in Combination With Human Chorionic Gonadotropin (hCG) in Adolescent Males With Hypogonadotropic Hypogonadism (HH) (MK-8962-043)

Phase 3

Completed

Conditions: Hypogonadotropic Hypogonadism

Interventions: Drug: Corifollitropin alfa
Drug: hCG

First Posted Date: 2017-01-12

Last Posted Date: 2024-05-23

Lead Sponsor: Organon and Co

Target Recruit Count: 17

Registration Number: NCT03019575

Locations: 🇧🇷
Hosp das Clinicas da Faculdade de Medicina da Univ de Sao Paulo ( Site 0015), Sao Paulo, Brazil
🇲🇽
Hospital Infantil de Mexico Federico Gomez ( Site 0006), Mexico City, Mexico
🇷🇺
City children polyclinic #44 ( Site 0025), Saint Petersburg, Russian Federation

and more 12 locations

A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-833)

Phase 3

Completed

Conditions: Familial Hypercholesterolemia
Hypercholesterolemia

Interventions: Drug: Ezetimibe
Drug: Rosuvastatin

First Posted Date: 2016-04-22

Last Posted Date: 2024-05-16

Lead Sponsor: Organon and Co

Target Recruit Count: 135

Registration Number: NCT02748057

Study of Efficacy and Long-Term Safety of Mometasone Furoate in Combination With Formoterol Fumarate Versus Mometasone Furoate in Children (5 to 11 Years of Age) With Persistent Asthma (MK-0887A-087)

Phase 3

Completed

Conditions: Asthma

Interventions: Drug: MF MDI 100 mcg BID (Open Label)
Drug: MF/F MDI 100/10 mcg BID
Drug: MF MDI 100 mcg BID
Drug: Albuterol/Salbutamol PRN
Drug: Prednisone/Prednisolone

First Posted Date: 2016-04-18

Last Posted Date: 2024-05-16

Lead Sponsor: Organon and Co

Target Recruit Count: 181

Registration Number: NCT02741271

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy